JP2016512818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512818A5 JP2016512818A5 JP2016500735A JP2016500735A JP2016512818A5 JP 2016512818 A5 JP2016512818 A5 JP 2016512818A5 JP 2016500735 A JP2016500735 A JP 2016500735A JP 2016500735 A JP2016500735 A JP 2016500735A JP 2016512818 A5 JP2016512818 A5 JP 2016512818A5
- Authority
- JP
- Japan
- Prior art keywords
- tetrandrine
- pharmaceutical formulation
- acid salt
- dibasic acid
- family member
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 claims 54
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 claims 32
- 239000002253 acid Substances 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 11
- 239000000243 solution Substances 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 6
- 229920000881 Modified starch Polymers 0.000 claims 5
- 235000019359 magnesium stearate Nutrition 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 3
- 239000012266 salt solution Substances 0.000 claims 3
- 239000007921 spray Substances 0.000 claims 3
- 239000006199 nebulizer Substances 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792849P | 2013-03-15 | 2013-03-15 | |
| US61/792,849 | 2013-03-15 | ||
| PCT/US2014/021195 WO2014149848A1 (en) | 2013-03-15 | 2014-03-06 | Tetrandrine family pharmaceutical formulations and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512818A JP2016512818A (ja) | 2016-05-09 |
| JP2016512818A5 true JP2016512818A5 (enExample) | 2017-04-06 |
Family
ID=51529969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016500735A Pending JP2016512818A (ja) | 2013-03-15 | 2014-03-06 | テトランドリンファミリーの医薬製剤及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9517234B2 (enExample) |
| EP (1) | EP2968310A4 (enExample) |
| JP (1) | JP2016512818A (enExample) |
| KR (1) | KR20150142691A (enExample) |
| CN (1) | CN105358149A (enExample) |
| MX (1) | MX2015013155A (enExample) |
| WO (1) | WO2014149848A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10576077B2 (en) | 2015-03-23 | 2020-03-03 | Southwest Research Institute | Pharmaceutical salt forms of Cepharanthine and Tetrandrine |
| CN107260694A (zh) * | 2017-06-14 | 2017-10-20 | 广西大海阳光药业有限公司 | 一种治疗硅肺、风湿痛、关节痛及神经痛的长效新制剂 |
| CN112402419B (zh) * | 2019-08-23 | 2023-12-08 | 华东理工大学 | 海兰地嗪或其药学上可接受的盐在糖尿病或糖尿病并发症药物中的应用 |
| CN111675717B (zh) * | 2020-06-21 | 2023-04-07 | 兰州理工大学 | 粉防己单体化合物及其提取方法和用途 |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN114159438B (zh) * | 2021-11-30 | 2023-07-18 | 首都医科大学附属北京安定医院 | 海兰地嗪及其衍生物在制备治疗抑郁症药物中的应用及所制备的抗抑郁药物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4569852A (en) * | 1983-08-23 | 1986-02-11 | Warner-Lambert Company | Maintenance of flavor intensity in pressed tablets |
| JPH0678232B2 (ja) * | 1986-03-07 | 1994-10-05 | 株式会社ツムラ | アンジオテンシンｉ転換酵素阻害剤 |
| JPH0678231B2 (ja) * | 1986-03-08 | 1994-10-05 | 株式会社ツムラ | 血液粘度低下剤 |
| JPH0733388B2 (ja) * | 1987-01-22 | 1995-04-12 | 株式会社ツムラ | 新規アルカロイド |
| JPH02243627A (ja) * | 1989-03-16 | 1990-09-27 | Tsumura & Co | 狭心症治療薬 |
| US5332747A (en) | 1989-09-28 | 1994-07-26 | Cancer Biologics Of America, Inc. | Method for potentiating primary drugs in treating multidrug resistant parasitic disease cells |
| US6911454B1 (en) | 1989-09-28 | 2005-06-28 | Cancer Biologics Of America, Inc. | Method for potentiating primary drugs in treating multidrug resistant disease |
| US5025020A (en) | 1989-09-28 | 1991-06-18 | Cancer Biologics Of America, Inc. | Use of tetrandrine and its derivatives to treat malaria |
| JPH0499723A (ja) * | 1990-08-17 | 1992-03-31 | Kaken Shiyouyaku Kk | ウイルス・ゲノム不活化剤 |
| US5192802A (en) * | 1991-09-25 | 1993-03-09 | Mcneil-Ppc, Inc. | Bioadhesive pharmaceutical carrier |
| US5627195A (en) * | 1995-04-11 | 1997-05-06 | Massachusetts Eye And Ear Infirmary | Treatment for ocular inflammation |
| US6218541B1 (en) | 1999-06-28 | 2001-04-17 | Cba, International, Inc. | Method for extracting bisbenzylisoquinolines |
| IL144760A0 (en) * | 1999-12-08 | 2002-06-30 | Pharmacia Corp | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| US20050245559A1 (en) * | 2004-01-23 | 2005-11-03 | Koul Hari K | Treatment and prevention of prostate cancer |
| MX2009000923A (es) * | 2006-08-04 | 2009-03-09 | Agi Therapeutics Res Ltd | Metodos para tratar cuando menos una condicion que tiene receptor de mt1, receptor de 5ht2b, y actividad de canal de calcio tipo l. |
| AU2009215514B9 (en) * | 2008-02-20 | 2014-01-30 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
| EP2241561A1 (en) | 2009-04-16 | 2010-10-20 | Neuron Biopharma, S.A. | Neuroprotective, hypocholesterolemic and antiepileptic compound |
| WO2011056965A1 (en) | 2009-11-05 | 2011-05-12 | Cba International, Inc. | Method for extracting and purifying bisbenzylisoquinolines |
| EP2491930A1 (en) | 2011-02-25 | 2012-08-29 | Deva Holding Anonim Sirketi | Pharmaceutical combination of betahistine and trimetazidine |
| CN104955330A (zh) * | 2012-09-13 | 2015-09-30 | Cba制药有限公司 | 粉防己碱药物制剂及方法 |
| CN102898433B (zh) * | 2012-09-26 | 2015-04-15 | 中国医药研究开发中心有限公司 | 一种汉防己甲素的没食子酸盐、其药物组合物、其制备方法及其用途 |
| JP2015531355A (ja) * | 2012-09-28 | 2015-11-02 | ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | 腫瘍治療のための薬剤組成物及びその適用 |
-
2014
- 2014-03-06 EP EP14767576.3A patent/EP2968310A4/en not_active Withdrawn
- 2014-03-06 KR KR1020157029740A patent/KR20150142691A/ko not_active Ceased
- 2014-03-06 US US14/199,235 patent/US9517234B2/en active Active
- 2014-03-06 CN CN201480028296.6A patent/CN105358149A/zh active Pending
- 2014-03-06 MX MX2015013155A patent/MX2015013155A/es unknown
- 2014-03-06 WO PCT/US2014/021195 patent/WO2014149848A1/en not_active Ceased
- 2014-03-06 JP JP2016500735A patent/JP2016512818A/ja active Pending
-
2016
- 2016-11-08 US US15/346,022 patent/US10023584B2/en active Active
- 2016-11-08 US US15/346,054 patent/US20170050976A1/en not_active Abandoned
-
2018
- 2018-06-20 US US16/012,872 patent/US10815243B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512818A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2018534348A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2017057230A5 (enExample) | ||
| JP2015057436A5 (enExample) | ||
| JP2011051993A5 (enExample) | ||
| EP4523752A3 (en) | Film formulations containing dexmedetomidine and methods of producing them | |
| CA2637765A1 (en) | Benzamide and heteroarene derivatives | |
| JP2017537066A5 (enExample) | ||
| RU2016122609A (ru) | Составы соединений азаиндола | |
| JP2019516684A5 (enExample) | ||
| JP2017537126A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| JP2013513612A5 (enExample) | ||
| NZ714963A (en) | Compositions and methods for treating anemia | |
| JP2016510326A5 (enExample) | ||
| CN115315423A (zh) | 取代芳基类化合物 | |
| JP2014512355A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| JP2014511897A5 (enExample) | ||
| JP2016512818A (ja) | テトランドリンファミリーの医薬製剤及び方法 | |
| JP2014148552A5 (enExample) |